back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2026-03-13 12:58 Tx date 2026-03-12 |
$MSCL
Satellos Bioscience Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Holder: Arlington Capital Holdings Inc. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
+15,000 vol |
15,000 | |
| Filed 2026-03-13 12:42 Tx date 2025-11-13 |
$MSCL
Satellos Bioscience Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Holder: Arlington Capital Holdings Inc. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2026-02-18 14:21 Tx date 2026-01-30 |
$MSCL
Satellos Bioscience Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-202,834 vol |
18,439 | |
| Filed 2025-11-18 15:17 Tx date 2025-11-14 |
$MSCL
Satellos Bioscience Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$152,678
+221,273 vol $0.69 each |
221,273 | |
| Filed 2025-11-18 15:14 Tx date 2025-11-13 |
$MSCL
Satellos Bioscience Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-07-26 10:41 Tx date 2021-07-20 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
56 - Grant of rights
|
+847,977 vol |
847,977 | |
| Filed 2021-07-26 10:38 Tx date 2014-10-08 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Restricted Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-07-26 10:36 Tx date 2021-07-20 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
38 - Redemption, retraction, cancellation, repurchase
|
-463,000 vol |
0 | |
| Filed 2018-10-29 Tx date 2018-06-01 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$15,000
+75,000 vol $0.20 each |
313,000 | |
| Filed 2018-10-29 Tx date 2018-10-23 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$15,000
+150,000 vol $0.10 each |
463,000 | |
| Filed 2018-10-29 Tx date 2017-07-24 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$15,000
+50,000 vol $0.30 each |
238,000 | |
| Filed 2017-03-14 Tx date 2016-06-21 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$27,300
+390,000 vol $0.07 each |
940,000 | |
| Filed 2017-03-14 Tx date 2017-03-10 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-532,000 vol |
133,000 | |
| Filed 2017-03-14 Tx date 2017-03-10 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
-752,000 vol |
188,000 | |
| Filed 2017-01-19 Tx date 2017-01-18 |
$IGX
IntelGenx Technologies Corp. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
125,000 | |
| Filed 2016-09-20 Tx date 2016-08-09 |
$IGX
IntelGenx Technologies Corp. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-09-20 Tx date 2016-09-15 |
$IGX
IntelGenx Technologies Corp. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
75,000 | |
| Filed 2016-05-08 Tx date 2014-10-08 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2016-05-08 Tx date 2016-05-03 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$16,200
+540,000 vol $0.03 each |
665,000 | |
| Filed 2016-05-08 Tx date 2016-05-03 |
$KNE
Kane Biotech Inc. |
Nawacki, Mark Henry
4 - Director of Issuer
Direct Ownership
|
Common Shares
56 - Grant of rights
|
+535,000 vol |
665,000 |